Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 248-655-3 | CAS number: 27776-21-2
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
In accordance with Regulation (EU) No. 1907/2006, Annex VI and VII, following in vitro tests were performed and are reported here:
- reverse mutation assay in vitro in bacteria,
- forward mutation assay in vitro in mammalian cells,
- Micro Nucleus assay in vitro in mammalian cells,
All tests were performed according to international Guidelines and validity criteria are fulfilled.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (positive)
Genetic toxicity in vivo
Description of key information
In accordance with Regulation (EU) No. 1907/2006, Annex VI and VII, IX and with regard to positive results in available in vitro tests following in vivo tests were performed and are reported here:
- Comet Assay in Stomach and Liver of the Rat,
- Micronucleus test in Bone Marrow Cells
All tests were performed according to international Guidelines and validity criteria are fulfilled.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Mode of Action Analysis / Human Relevance Framework
From the available in-vitro studies, no clear mode of action is determinable:
in bacteria gene mutation occurs without metabolic activation,
in mammalian cells, gen mutations occurs only in the presence of metabolic activation.
For both assays, genotoxicity is observed only in high doses.
The micro nucelus test in mammalian cells showed effects also at lower doses with and without metabolic activation.
These results show that 2,2'-Azobis[2-(2-imidazolin-2-yl)propane] dihydrochloride has the ability to damage the DNA
of bacteria as well as specific mammalian cells when the cells are directly exposed.
The available in vivo tests did not show any signs of genotoxicity.
The bioavailability of the substance was demonstrated in these tests by cytotoxic effects.
Additional information
Justification for classification or non-classification
The available in vitro tests show positive results for the genotoxicity endpoint, however the available in vivo tests do not confirm this.
Two in vivo genotoxicity tests were performed testing the Endpoints gene mutation and chromosome aberration. No Genotoxic effects were observed in these tests.
The substance Azobis(Isobutyronitrile) which exhibits the general structural elements of 2,2'-Azobis[2 -(2 -imidazolin-2 -yl)propane] dihydrochloride is not classified as Mutagen (cat. 1 or 2).
Therefore, laying down the considerations in Regulation (EC) No. 1272/2008 Annex I, table 3.5.1., the data is conclusive but not sufficient for classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
